$MTNB
Matinas BioPharma Holdings Inc

2014 Q4 Form 10-Q Financial Statement

#000114420414068425 Filed on November 14, 2014

View on sec.gov

Income Statement

Concept 2014 Q4 2014 Q3 2013 Q3
Revenue $0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin
YoY Change
% of Gross Profit
Research & Development $1.070M $745.0K
YoY Change 43.59%
% of Gross Profit
Depreciation & Amortization -$10.00K $30.00K $0.00
YoY Change
% of Gross Profit
Operating Expenses $2.605M $1.453M
YoY Change 79.3%
Operating Profit -$2.605M
YoY Change
Interest Expense
YoY Change
% of Operating Profit
Other Income/Expense, Net -$6.495K
YoY Change
Pretax Income
YoY Change
Income Tax
% Of Pretax Income
Net Earnings -$2.612M -$1.456M
YoY Change 79.34%
Net Earnings / Revenue
Basic Earnings Per Share
Diluted Earnings Per Share
COMMON SHARES
Basic Shares Outstanding 32.17M shares 32.00M shares
Diluted Shares Outstanding

Balance Sheet

Concept 2014 Q4 2014 Q3 2013 Q3
SHORT-TERM ASSETS
Cash & Short-Term Investments $2.590M $5.010M $12.57M
YoY Change -76.11% -60.14%
Cash & Equivalents $2.591M $5.007M $12.57M
Short-Term Investments
Other Short-Term Assets $210.0K $110.0K $30.00K
YoY Change 162.5% 266.67%
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets $2.805M $5.110M $12.60M
YoY Change -74.32% -59.44%
LONG-TERM ASSETS
Property, Plant & Equipment $340.0K $360.0K $30.00K
YoY Change 265.36% 1100.0%
Goodwill $0.00
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $220.0K $320.0K
YoY Change -31.25%
Total Long-Term Assets $556.3K $680.0K $30.00K
YoY Change 36.07% 2166.67%
TOTAL ASSETS
Total Short-Term Assets $2.805M $5.110M $12.60M
Total Long-Term Assets $556.3K $680.0K $30.00K
Total Assets $3.361M $5.790M $12.63M
YoY Change -70.34% -54.16%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $271.2K $210.0K $260.0K
YoY Change -31.66% -19.23%
Accrued Expenses $802.7K $764.7K $240.0K
YoY Change 73.68% 218.65%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due $40.00K $40.00K
YoY Change
Total Short-Term Liabilities $1.118M $1.021M $500.0K
YoY Change 30.19% 104.13%
LONG-TERM LIABILITIES
Long-Term Debt $20.00K $20.00K $0.00
YoY Change
Other Long-Term Liabilities
YoY Change
Total Long-Term Liabilities $20.00K $20.00K $0.00
YoY Change
TOTAL LIABILITIES
Total Short-Term Liabilities $1.118M $1.021M $500.0K
Total Long-Term Liabilities $20.00K $20.00K $0.00
Total Liabilities $1.134M $1.043M $500.0K
YoY Change 31.97% 108.62%
SHAREHOLDERS EQUITY
Retained Earnings -$14.05M -$11.01M
YoY Change 266.82%
Common Stock $3.230K $3.217K
YoY Change 0.94%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $2.228M $4.746M $12.13M
YoY Change
Total Liabilities & Shareholders Equity $3.361M $5.789M $12.63M
YoY Change -70.34% -54.17%

Cashflow Statement

Concept 2014 Q4 2014 Q3 2013 Q3
OPERATING ACTIVITIES
Net Income -$2.612M -$1.456M
YoY Change 79.34%
Depreciation, Depletion And Amortization -$10.00K $30.00K $0.00
YoY Change
Cash From Operating Activities -$2.410M -$1.610M -$890.0K
YoY Change 44.31% 80.9% -9000.0%
INVESTING ACTIVITIES
Capital Expenditures $0.00 -$30.00K -$30.00K
YoY Change -100.0% 0.0%
Acquisitions
YoY Change
Other Investing Activities
YoY Change
Cash From Investing Activities $0.00 -$30.00K -$30.00K
YoY Change -100.0% 0.0%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 0.000 0.000 13.03M
YoY Change -100.0% -130400.0%
NET CHANGE
Cash From Operating Activities -2.410M -1.610M -890.0K
Cash From Investing Activities 0.000 -30.00K -30.00K
Cash From Financing Activities 0.000 0.000 13.03M
Net Change In Cash -2.410M -1.640M 12.11M
YoY Change 39.31% -113.54%
FREE CASH FLOW
Cash From Operating Activities -$2.410M -$1.610M -$890.0K
Capital Expenditures $0.00 -$30.00K -$30.00K
Free Cash Flow -$2.410M -$1.580M -$860.0K
YoY Change 49.69% 83.72%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2013Q4 us-gaap Liabilities
Liabilities
858968 USD
us-gaap Use Of Estimates
UseOfEstimates
<div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt"> </div> <table style="LINE-HEIGHT: 115%; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt" border="0" cellspacing="0" cellpadding="0"> <tr> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 0.3pt; PADDING-RIGHT: 0in; PADDING-TOP: 0in" valign="top" width="0"></td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 0.5in; PADDING-RIGHT: 0in; PADDING-TOP: 0in" valign="top" width="48"> <div style="CLEAR:both;MARGIN: 0in 0in 0pt; FONT-FAMILY: Times New Roman,serif; FONT-SIZE: 12pt"> <b><font style="FONT-SIZE: 10pt">[2]</font></b></div> </td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; PADDING-RIGHT: 0in; PADDING-TOP: 0in" valign="top"> <div style="CLEAR:both;MARGIN: 0in 0in 0pt; FONT-FAMILY: Times New Roman,serif; FONT-SIZE: 12pt" align="justify"><b><font style="FONT-SIZE: 10pt">Use of Estimates</font></b></div> </td> </tr> </table> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt 0.5in" align="justify"><font style="FONT-SIZE: 10pt">&#160;</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt 0.5in" align="justify"><font style="FONT-SIZE: 10pt">The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities at the date of the financial statements and the reported amounts of revenue and expenses during the reporting period. Actual results could differ from those estimates.</font></div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table>
us-gaap Concentration Risk Credit Risk
ConcentrationRiskCreditRisk
<div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt"> </div> <table style="LINE-HEIGHT: 115%; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt" border="0" cellspacing="0" cellpadding="0"> <tr> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 0.3pt; PADDING-RIGHT: 0in; PADDING-TOP: 0in" valign="top" width="0"></td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 0.5in; PADDING-RIGHT: 0in; PADDING-TOP: 0in" valign="top" width="48"> <div style="CLEAR:both;MARGIN: 0in 0in 0pt; FONT-FAMILY: Times New Roman,serif; FONT-SIZE: 12pt"> <b><font style="FONT-SIZE: 10pt">[4]</font></b></div> </td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; PADDING-RIGHT: 0in; PADDING-TOP: 0in" valign="top"> <div style="CLEAR:both;MARGIN: 0in 0in 0pt; FONT-FAMILY: Times New Roman,serif; FONT-SIZE: 12pt" align="justify"><b><font style="FONT-SIZE: 10pt">Concentration of Credit Risk</font></b></div> </td> </tr> </table> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt 0.5in" align="justify"><font style="FONT-SIZE: 10pt">&#160;</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt 0.5in" align="justify"><font style="FONT-SIZE: 10pt">The Company&#8217;s financial instruments that are exposed to concentrations of credit risk consist primarily of cash and cash equivalents. Cash balances are maintained principally at one major U.S. financial institution and are insured by the Federal Deposit Insurance Corporation (&#8220;FDIC&#8221;) up to regulatory limits. At various times throughout the period ended September 30, 2014, the Company&#8217;s cash balances exceeded the FDIC insurance limit. The Company has not experienced any losses in such accounts.</font></div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table>
CY2013Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
462200 USD
CY2014Q3 us-gaap Capital Lease Obligations Current
CapitalLeaseObligationsCurrent
44086 USD
CY2013Q4 us-gaap Capital Lease Obligations Current
CapitalLeaseObligationsCurrent
0 USD
CY2014Q3 us-gaap Liabilities Current
LiabilitiesCurrent
1020665 USD
CY2013Q4 us-gaap Liabilities Current
LiabilitiesCurrent
858968 USD
CY2014Q3 us-gaap Capital Lease Obligations Noncurrent
CapitalLeaseObligationsNoncurrent
22455 USD
CY2013Q4 us-gaap Capital Lease Obligations Noncurrent
CapitalLeaseObligationsNoncurrent
0 USD
CY2014Q3 us-gaap Liabilities
Liabilities
1043120 USD
CY2014Q3 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
764748 USD
CY2014Q3 us-gaap Common Stock Value
CommonStockValue
3217 USD
CY2013Q4 us-gaap Common Stock Value
CommonStockValue
3200 USD
CY2014Q3 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
15749890 USD
CY2013Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
14302307 USD
CY2014Q3 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-11007441 USD
CY2013Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-3830719 USD
CY2014Q3 us-gaap Stockholders Equity
StockholdersEquity
4745666 USD
CY2013Q4 us-gaap Stockholders Equity
StockholdersEquity
10474788 USD
CY2014Q3 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
5788786 USD
CY2013Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
11333756 USD
mtnb Stock To Be Issued Upon Exercise
StockToBeIssuedUponExercise
17085000 shares
mtnb Stock To Be Issued Upon Exercise
StockToBeIssuedUponExercise
20665000 shares
CY2013Q2 us-gaap Stock Issued During Period Shares New Issues
StockIssuedDuringPeriodSharesNewIssues
7500000 shares
CY2013Q2 mtnb Warrants Issued For Purchase Of Common Stock
WarrantsIssuedForPurchaseOfCommonStock
3750000 shares
CY2013Q2 mtnb Common Stock To Be Issued Upon Exercise Of Warrants
CommonStockToBeIssuedUponExerciseOfWarrants
3750000 shares
CY2013Q2 invest Investment Warrants Exercise Price
InvestmentWarrantsExercisePrice
2.00
CY2013Q2 us-gaap Proceeds From Issuance Of Warrants
ProceedsFromIssuanceOfWarrants
375000 USD
CY2013Q2 mtnb Stock And Warrants Issued Price Per Unit
StockAndWarrantsIssuedPricePerUnit
0.10
CY2013Q3 us-gaap Payments Of Stock Issuance Costs
PaymentsOfStockIssuanceCosts
2400000 USD
CY2013Q3 mtnb Placement Agent Cash Fees And Expenses
PlacementAgentCashFeesAndExpenses
1950000 USD
CY2013Q3 mtnb External Legal Costs
ExternalLegalCosts
425000 USD
CY2013Q3 mtnb Securities Penalty Payment Description
SecuritiesPenaltyPaymentDescription
Holdings shall pay to each holder of registrable securities purchased in 2013 Private Placement an amount in cash equal to half of one percent (0.5%) of such holder&#8217;s investment amount on every thirty (30) day anniversary of such failure to maintain the registration statement until such failure was cured;
CY2013Q3 mtnb Effectiveness Of Registration Statement Description
EffectivenessOfRegistrationStatementDescription
If the Company does not maintain the effectiveness of the registration statement during the Effectiveness Period, subject to certain limitations and the right of the Company to suspend the use of the prospectus for certain periods, Holdings shall pay to each holder of registrable securities purchased in 2013 Private Placement an amount in cash equal to half of one percent (0.5%) of such holders investment amount on every thirty (30) day anniversary of such failure to maintain the registration statement until such failure was cured;
CY2014Q3 us-gaap Class Of Warrant Or Right Outstanding
ClassOfWarrantOrRightOutstanding
15250000 shares
CY2014Q3 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2013Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2014Q3 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
150000000 shares
CY2013Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
150000000 shares
CY2014Q3 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
32167650 shares
CY2013Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
32000000 shares
CY2014Q3 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
32167650 shares
CY2013Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
32000000 shares
CY2013Q3 us-gaap Common Stock Capital Shares Reserved For Future Issuance
CommonStockCapitalSharesReservedForFutureIssuance
8250000 shares
CY2014Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Percentage Of Outstanding Stock Maximum
ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum
0.04 pure
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
288518 USD
us-gaap Net Cash Provided By Used In Investing Activities Continuing Operations
NetCashProvidedByUsedInInvestingActivitiesContinuingOperations
-28298 USD
CY2014Q2 mtnb Sharebased Compensation Arrangement By Sharebased Payment Award Increase Of Shares Offering Date
SharebasedCompensationArrangementBySharebasedPaymentAwardIncreaseOfSharesOfferingDate
January 1, 2015
CY2014Q3 us-gaap Operating Leases Future Minimum Payments Due Current
OperatingLeasesFutureMinimumPaymentsDueCurrent
44384 USD
CY2014Q3 us-gaap Operating Leases Future Minimum Payments Due In Two Years
OperatingLeasesFutureMinimumPaymentsDueInTwoYears
154140 USD
CY2014Q3 us-gaap Operating Leases Future Minimum Payments Due In Three Years
OperatingLeasesFutureMinimumPaymentsDueInThreeYears
157076 USD
CY2014Q3 us-gaap Operating Leases Future Minimum Payments Due In Four Years
OperatingLeasesFutureMinimumPaymentsDueInFourYears
160014 USD
CY2014Q3 us-gaap Operating Leases Future Minimum Payments Due In Five Years
OperatingLeasesFutureMinimumPaymentsDueInFiveYears
582797 USD
CY2014Q3 us-gaap Operating Leases Future Minimum Payments Due
OperatingLeasesFutureMinimumPaymentsDue
1098411 USD
CY2014Q3 us-gaap Security Deposit
SecurityDeposit
300000 USD
CY2013Q4 us-gaap Lessor Leasing Arrangements Operating Leases Term Of Contract
LessorLeasingArrangementsOperatingLeasesTermOfContract
P7Y
CY2014Q1 us-gaap Operating Leases Rent Expense Net
OperatingLeasesRentExpenseNet
2072 USD
CY2014Q2 us-gaap Operating Leases Rent Expense Net
OperatingLeasesRentExpenseNet
12723 USD
mtnb Security Deposits Reduced By Straight Line Basis Description
SecurityDepositsReducedByStraightLineBasisDescription
Starting June1, 2015, this deposit can be reduced by $100,000 on an annual basis, down to $50,000, as long as the Company makes timely rental payments.
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
1034700 USD
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
3261747 USD
CY2013Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
745000 USD
CY2014Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
1069716 USD
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
873888 USD
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
3893100 USD
CY2013Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
708084 USD
CY2014Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
1535617 USD
us-gaap Operating Expenses
OperatingExpenses
1908588 USD
us-gaap Operating Expenses
OperatingExpenses
7154847 USD
CY2013Q3 us-gaap Operating Expenses
OperatingExpenses
1453084 USD
CY2014Q3 us-gaap Operating Expenses
OperatingExpenses
2605333 USD
us-gaap Income Loss From Continuing Operations
IncomeLossFromContinuingOperations
-1908588 USD
us-gaap Income Loss From Continuing Operations
IncomeLossFromContinuingOperations
-7154847 USD
CY2013Q3 us-gaap Income Loss From Continuing Operations
IncomeLossFromContinuingOperations
-1453084 USD
CY2014Q3 us-gaap Income Loss From Continuing Operations
IncomeLossFromContinuingOperations
-2605333 USD
us-gaap Extraordinary Item Gain Or Loss Net Of Tax Attributable To Reporting Entity
ExtraordinaryItemGainOrLossNetOfTaxAttributableToReportingEntity
-3202 USD
us-gaap Extraordinary Item Gain Or Loss Net Of Tax Attributable To Reporting Entity
ExtraordinaryItemGainOrLossNetOfTaxAttributableToReportingEntity
-21876 USD
CY2013Q3 us-gaap Extraordinary Item Gain Or Loss Net Of Tax Attributable To Reporting Entity
ExtraordinaryItemGainOrLossNetOfTaxAttributableToReportingEntity
-3259 USD
CY2014Q3 us-gaap Extraordinary Item Gain Or Loss Net Of Tax Attributable To Reporting Entity
ExtraordinaryItemGainOrLossNetOfTaxAttributableToReportingEntity
-6495 USD
us-gaap Net Income Loss
NetIncomeLoss
-1911790 USD
us-gaap Net Income Loss
NetIncomeLoss
-7176723 USD
CY2013Q3 us-gaap Net Income Loss
NetIncomeLoss
-1456343 USD
CY2014Q3 us-gaap Net Income Loss
NetIncomeLoss
-2611828 USD
us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.13
us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.22
CY2013Q3 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.10
CY2014Q3 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.08
us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
14895604 shares
us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
32020265 shares
CY2013Q3 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
14895604 shares
CY2014Q3 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
32060796 shares
us-gaap Depreciation
Depreciation
662 USD
us-gaap Depreciation
Depreciation
51495 USD
us-gaap Share Based Compensation
ShareBasedCompensation
178020 USD
us-gaap Share Based Compensation
ShareBasedCompensation
1446600 USD
us-gaap Increase Decrease In Prepaid Expense
IncreaseDecreaseInPrepaidExpense
30392 USD
us-gaap Increase Decrease In Prepaid Expense
IncreaseDecreaseInPrepaidExpense
47070 USD
us-gaap Increase Decrease In Other Operating Liabilities
IncreaseDecreaseInOtherOperatingLiabilities
241466 USD
us-gaap Increase Decrease In Other Operating Liabilities
IncreaseDecreaseInOtherOperatingLiabilities
370089 USD
us-gaap Net Cash Provided By Used In Investing Activities Continuing Operations
NetCashProvidedByUsedInInvestingActivitiesContinuingOperations
-288518 USD
us-gaap Repayments Of Related Party Debt
RepaymentsOfRelatedPartyDebt
24100 USD
us-gaap Repayments Of Related Party Debt
RepaymentsOfRelatedPartyDebt
0 USD
us-gaap Proceeds From Issuance Of Redeemable Convertible Preferred Stock
ProceedsFromIssuanceOfRedeemableConvertiblePreferredStock
500001 USD
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
200469 USD
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-184937 USD
us-gaap Net Cash Provided By Used In Operating Activities Continuing Operations
NetCashProvidedByUsedInOperatingActivitiesContinuingOperations
-1321565 USD
us-gaap Net Cash Provided By Used In Operating Activities Continuing Operations
NetCashProvidedByUsedInOperatingActivitiesContinuingOperations
-5545137 USD
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
28298 USD
us-gaap Proceeds From Issuance Of Redeemable Convertible Preferred Stock
ProceedsFromIssuanceOfRedeemableConvertiblePreferredStock
0 USD
mtnb Payments Of Preferred Stock Issuance Costs
PaymentsOfPreferredStockIssuanceCosts
4140 USD
mtnb Payments Of Preferred Stock Issuance Costs
PaymentsOfPreferredStockIssuanceCosts
0 USD
us-gaap Net Cash Provided By Used In Financing Activities Continuing Operations
NetCashProvidedByUsedInFinancingActivitiesContinuingOperations
13498087 USD
us-gaap Net Cash Provided By Used In Financing Activities Continuing Operations
NetCashProvidedByUsedInFinancingActivitiesContinuingOperations
0 USD
us-gaap Net Cash Provided By Used In Continuing Operations
NetCashProvidedByUsedInContinuingOperations
12148224 USD
us-gaap Net Cash Provided By Used In Continuing Operations
NetCashProvidedByUsedInContinuingOperations
-5833655 USD
CY2012Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
424364 USD
CY2013Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
12572588 USD
dei Document Type
DocumentType
10-Q
dei Amendment Flag
AmendmentFlag
false
dei Document Period End Date
DocumentPeriodEndDate
2014-09-30
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2014
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q3
dei Entity Registrant Name
EntityRegistrantName
Matinas BioPharma Holdings, Inc.
dei Entity Central Index Key
EntityCentralIndexKey
0001582554
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
dei Entity Filer Category
EntityFilerCategory
Smaller Reporting Company
dei Trading Symbol
TradingSymbol
MTNB
CY2014Q4 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
32167650 shares
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
15000000 USD
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
0 USD
us-gaap Payments Of Stock Issuance Costs
PaymentsOfStockIssuanceCosts
2378674 USD
us-gaap Payments Of Stock Issuance Costs
PaymentsOfStockIssuanceCosts
0 USD
us-gaap Proceeds From Other Equity
ProceedsFromOtherEquity
375000 USD
us-gaap Proceeds From Other Equity
ProceedsFromOtherEquity
0 USD
us-gaap Proceeds From Issuance Of Warrants
ProceedsFromIssuanceOfWarrants
10000 USD
us-gaap Proceeds From Issuance Of Warrants
ProceedsFromIssuanceOfWarrants
0 USD
us-gaap Increase Decrease In Deposits
IncreaseDecreaseInDeposits
0 USD
us-gaap Increase Decrease In Deposits
IncreaseDecreaseInDeposits
-4591 USD
us-gaap Proceeds From Issuance Of Private Placement
ProceedsFromIssuanceOfPrivatePlacement
20000 USD
us-gaap Proceeds From Issuance Of Private Placement
ProceedsFromIssuanceOfPrivatePlacement
0 USD
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
178000 USD
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
1447000 USD
CY2013Q3 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
178000 USD
CY2014Q3 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
900000 USD
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
2380000 shares
us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
0 shares
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
100918 shares
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Expirations In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod
24082 shares
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
1.23
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
0.94
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Expirations In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice
0.94
CY2013Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
3160000 shares
CY2013Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
0.94
CY2014Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
5415000 shares
CY2014Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
1.07
CY2014Q3 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
424000 USD
CY2013Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
94000 USD
CY2014Q3 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
66000 USD
CY2013Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
1000 USD
CY2013Q4 us-gaap Security Deposit
SecurityDeposit
300000 USD

Files In Submission

Name View Source Status
0001144204-14-068425-index-headers.html Edgar Link pending
0001144204-14-068425-index.html Edgar Link pending
0001144204-14-068425.txt Edgar Link pending
0001144204-14-068425-xbrl.zip Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xls Edgar Link pending
Financial_Report.xlsx Edgar Link pending
mtnb-20140930.xml Edgar Link completed
mtnb-20140930.xsd Edgar Link pending
mtnb-20140930_cal.xml Edgar Link unprocessable
mtnb-20140930_def.xml Edgar Link unprocessable
mtnb-20140930_lab.xml Edgar Link unprocessable
mtnb-20140930_pre.xml Edgar Link unprocessable
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R4.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending
v393135_10q.htm Edgar Link pending
v393135_ex31-1.htm Edgar Link pending
v393135_ex31-2.htm Edgar Link pending
v393135_ex32-1.htm Edgar Link pending